Journal of Medicinal Chemistry
Article
cyclosporin A analogues as potential anti-HCV agents. Bioorg. Med.
Chem. Lett. 2010, 20, 6542−6546.
(34) Praveen Rao, P. N.; Amini, M.; Li, H.; Habeeb, A. G.; Knaus, E.
E. Design, synthesis, and biological evaluation of 6-substituted-3-(4-
methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of
diarylheterocyclic selective cyclooxygenase-2 inhibitors. J. Med. Chem.
2003, 46, 4872−4882.
(35) For some parasites, a 3-methyl group may abolish thiazolide
activity completely: Esposito, M.; Stettler, R.; Moores, S. L.; Pidathala,
C.; Muller, N.; Berry, N. G.; Stachulski, A. V.; Rossignol, J.-F.;
Hemphill, A. In vitro efficacy of nitazoxanide and other thiazolides
against Neospora caninum tachyzoites reveals anti-parasitic activity
independent of the nitro group. Antimicrob. Agents Chemother. 2005,
49, 3715−3723.
(36) Waisser, K.; Hladuvkova, J.; Kunes, J.; Kubicova, L.; Klimesova,
V.; Karajannis, P.; Kaustova, J. Synthesis and antimycobacterial activity
of salicylanilides substituted in position 5. Chem. Pap. 2001, 55, 121−
129.
(37) Podlogar, B. L.; Muegge, I.; Brice, L. J. Computational methods
to estimate drug development parameters. Curr. Opin. Drug Discovery
2001, 4, 102−109.
(19) (a) Zitzmann, N.; Mehta, A. S.; Carrouee, S.; Butters, T. D.;
Platt, F. M.; McCauley, J.; Blumberg, B. S.; Dwek, R. A.; Block, T. M.
Imino sugars inhibit the formation and secretion of bovine viral
diarrhea virus, a pestivirus model of hepatitis C virus: implications for
the development of broad spectrum anti-hepatitis virus agents. Proc.
Natl. Acad. Sci. U.S.A. 1999, 96, 11878−11882. (b) Ouzounov, S.;
Mehta, A.; Dwek, R. A.; Block, T. M.; Jordan, R. The combination of
interferon alpha-2b and n-butyl deoxynojirimycin has a greater than
additive antiviral effect upon production of infectious bovine viral
diarrhea virus (BVDV) in vitro: implications for hepatitis C virus
(HCV) therapy. Antiviral Res. 2008, 55, 425−435.
(20) Stachulski, A. V.; Pidathala, C.; Row, E. C.; Sharma, R.; Berry,
N. G.; Iqbal, M.; Bentley, J.; Allman, S. A.; Edwards, G.; Helm, A.;
Hellier, J.; Korba, B. E.; Semple, E. J.; Rossignol, J.-F. Thiazolides as
novel antiviral agents: 1. Inhibition of hepatitis B virus replication. J.
Med. Chem. 2011, 54, 4119−4132.
(21) Korba, B. E.; Montero, A. B.; Farrar, K.; Gaye, K.; Mukerjee, S.;
Ayers, M. S.; Rossignol, J.-F. Nitazoxanide, tizoxanide and other
thiazolides are potent inhibitors of hepatitis B virus and hepatitis C
virus replication. Antiviral Res. 2008, 77, 56−63.
(22) Rossignol, J.-F. Thiazolides: a new class of antiviral drugs. Expert
Opin. Drug Metab. Toxicol. 2009, 5, 667−674.
(23) Korba, B. E.; Elazar, M.; Lui, P.; Rossignol, J.-F.; Glenn, J. S.
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
Antimicrob. Agents Chemother. 2008, 52, 4069−4071.
(24) Yon, C.; Viswanathan, P.; Rossignol, J.-F.; Korba, B. E.
Mutations in HCV non-structural genes do not contribute to
resistance to nitazoxanide in replicon-containing cells. Antiviral Res.
2011, 91, 233−240.
(25) Rossignol, J.-F.; Elfert, A.; El-Gohary, Y.; Keeffe, E. B. Improved
virologic response in chronic hepatitis C genotype 4 treated with
nitazoxanide, peginterferon and ribavirin. Gastroenterology 2009, 136,
856−862.
(26) (a) Rossignol, J.-F.; Elferty, A.; Keeffe, E. B. Treatment of
chronic hepatitis C using a 4-week lead-in with nitazoxanide before
peginterferon plus nitazoxanide. J. Clin. Gastroenterol. 2010, 44, 504−
509. (b) Korba, B. E.; Elazar, M.; Lui, P.; Glenn, J. S.; Rossignol, J.-F.
Potential role for nitazoxanide in combination with STAT-C agents for
the inhibition of HCV replication without the development of
resistance. Hepatology 2008, 48 (Suppl.), 356A.
(38) Eriksson, L.; Jaworska, J.; Worth, A. P.; Cronin, M. T. D.;
McDowell, R. M. M.; Gramatica, P. Methods for reliability and
uncertainty assessment and for applicability evaluations of
classification- and regression-based QSARs. Environ. Health Perspect.
2003, 111, 1361−1375.
com/ (accessed Aug 19, 2011).
(40) DRAGON (Software for Molecular Descriptor Calculation),
(41) Guidance Document on The Validation of (Quantitative)
Structure−Activity Relationships [(Q)SAR] Models; OECD: Paris,
(42) Tropsha, A.; Gramatica, P.; Gombar, V. K. The importance of
being earnest: validation is the absolute essential for successful
application and interpretation of QSAR models. QSAR Comb. Sci.
2003, 22, 69−77.
(43) Kennard, R. W.; Stone, L. A. Computer aided design of
experiments. Technometric 1969, 11, 137−148.
(44) Golbraikh, A.; Tropsha, A. Beware of q(2)! J. Mol. Graphics
2002, 20, 269−276.
(45) (a) Jorissen, R. N.; Gilson, M. K. Virtual screening of molecular
databases using a support vector machine. J. Chem. Inf. Model. 2005,
45, 549−561. (b) Li, H.; Yap, C. W.; Xue, Y.; Li, Z. R.; Ung, C. Y.;
Han, L. Y.; Chen, Y. Z. Statistical learning approach for predicting
specific pharmacodynamic, pharmacokinetic or toxicological properties
of pharmaceutical agents. Drug Dev. Res. 2006, 66, 245−259.
(46) Sarrazin, C.; Kieffer, T. L.; Bartels, D.; Hanzelka, B.; Muh, U.;
Welker, M.; Wincheringer, D.; Zhou, Y.; Chu, H.-M.; Lin, C.;
Weegink, C.; Reesink, H.; Zeuzem, S.; Kwong, A. D. Dynamic
hepatitis C virus genotypic and phenotypic changes in patients treated
with the protease inhibitor telaprevir. Gastroenterology 2007, 132,
1767−1777.
(47) Korba, B. E.; Glenn, J. S.; Ayers, M. S.; Rossignol, J.-F. Studies of
the potential for resistance to nitazoxanide or tizoxanide. J. Hepatol.
2008, 48, S11.
(48) Rossignol, J.-F.; La Frazia, S.; Chiappa, L.; Ciucci, A.; Santoro,
M. G. Thiazolides, a new class of anti-influenza molecules targeting
viral haemagglutinin at the post-translational level. J. Biol. Chem. 2009,
284, 29798−29808.
(49) Elazar, M.; Liu, M.; McKenna, S. A.; Liu, P.; Gehrig, E. A.;
Puglisi, J. D.; Rossignol, J.-F.; Glenn, J. S. The anti-hepatitis C agent
nitazoxanide induces phosphorylation of eukaryotic initiation factor 2
alpha via protein kinase activated by double-stranded RNA activation.
Gastroenterology 2009, 137, 1827−1835.
(50) Guo, L.; Wang, Q.-L.; Jiang, Q.-Q.; Jiang, Q.-J.; Jiang, Y.-B.
Anion-triggered substituent-dependent conformational switching of
salicylanilides. New hints for understanding the inhibitory mechanism
of salicylanilides. J. Org. Chem. 2007, 72, 9947−9953.
(27) Cavier, R.; Gayral, Ph.; Guillaumel, J.; Clavel, J. M.;
Demerseman, P.; Royer, R. Recherches sur les der
d’interet biologique. XVI. Relations entre structures et activites
protozoocides antheminthiques et molluscicides dans la serie du
́ ́ ́
ives nitres
́
̂
́
́
benzamido-2 nitro-5 thiazole. Eur. J. Med. Chem. 1978, 13, 539−543.
(28) Rossignol, J. F.; Cavier, R. New Derivatives of 2-Benzamido 5-
Nitrothiazoles. U.S. Patent 3,950,351, April 13, 1976.
(29) (a) Luo, Q.-L.; Li, J.-Y.; Liu, Z.-Y; Chen, L.-L.; Li, J.; Ye, Q.-Z.;
Nan, F.-J. Inhibitors of type I MetAPs containing pyridine-2-carboxylic
acid thiazol-2-ylamide. Part I: SAR studies on the determination of the
key scaffold. Bioorg. Med. Chem. Lett. 2005, 15, 635−638.
(b) Rossignol, J.-F.; Semple, J. E. Preparation of Thiazolylbenzamide
Derivatives for Use as Antiviral Hepatitis Agents. U.S. Pat. Appl. Publ.
20090036467, Feb 5, 2009. (c) U.S. Patent 2401522, 1943; Sandoz.
(30) Laduron, F.; Janousek, Z.; Viehe, H. G. α- or β-Trifluoromethyl
epoxysulfones: new C3 reagents for heterocyclisation. J. Fluorine Chem.
1995, 73, 83−86.
(31) Feiring, A. E. 1-(Trifluoromethy1)ethenyl phenyl selenide and1-
(trifluoromethy1)ethenyl phenyl sulfide. J. Org. Chem. 1980, 45,
1962−1964.
(32) Stanetty, P.; Schnurch, M.; Mereiter, K.; Mihovilovic, M. D.
Investigations of the halogen dance reaction on N-substituted 2-
thiazolamines. J. Org. Chem. 2005, 70, 567−574.
(33) Schiavi, B.; Ahond, A.; Poupat, C.; Potier, P. Preparation of N-
tert-butoxycarbonylthiourea opens the way to protected 2-
aminothiazoles. Synth. Commun. 2002, 32, 1671−1674.
8679
dx.doi.org/10.1021/jm201264t | J. Med. Chem. 2011, 54, 8670−8680